JS	O
ISH	O
-	O
ECCR	O
-3	O
A	O
NOVEL	O
ALGORITHM	B:C0002045
FOR	O
THE	O
CASE	O
DETECTION	B:C1511790
OF	O
THE	O
MOST	O
COMMON	O
FORM	O
OF	O
ENDOCRINE	B:C0264641
HYPERTENSION	I:C0264641
.	O

Primary	B:C1384514
aldosteronism	I:C1384514
(	O
Primary	B:C1384514
aldosteronism	I:C1384514
)	O
involves	O
more	O
than	O
11	O
%	O
of	O
patients	O
referred	O
to	O
specialized	O
hypertension	B:C0020538
centers	B:C0475309
and	O
,	O
therefore	O
,	O
is	O
much	O
more	O
common	O
than	O
commonly	O
held	O
.	O

Moreover	O
,	O
it	O
causes	O
a	O
damage	O
to	O
the	O
heart	B:C0018787
,	O
blood	B:C0005847
vessels	I:C0005847
and	O
kidneys	B:C0022646
,	O
which	O
translates	O
into	O
a	O
high	O
rate	O
of	O
cardiovascular	B:C1320716
events	I:C1320716
,	O
in	O
excess	O
to	O
the	O
degree	O
of	O
blood	B:C0497247
pressure	I:C0497247
raise	I:C0497247
.	O

Along	O
with	O
the	O
notion	O
that	O
a	O
timely	O
diagnosis	B:C0430022
entails	O
a	O
fundamental	O
step	O
for	O
the	O
choice	O
of	O
an	O
appropriate	O
therapy	B:C0087111
,	O
which	O
can	O
correct	O
the	O
arterial	B:C0020538
hypertension	I:C0020538
and	O
the	O
hypokalemia	B:C0020621
,	O
this	O
justifies	O
efforts	O
to	O
search	B:C0557959
for	O
Primary	B:C1384514
aldosteronism	I:C1384514
in	O
the	O
majority	O
of	O
the	O
patients	O
with	O
hypertension	B:C0020538
.	O

Unfortunately	O
,	O
because	O
of	O
the	O
lack	O
of	O
the	O
classical	O
signs	B:C0037088
,	O
as	O
spontaneous	O
or	O
drug	B:C0342591
-	I:C0342591
induced	I:C0342591
hypokalemia	I:C0342591
and	O
related	O
symptoms	B:C1457887
,	O
Primary	B:C1384514
aldosteronism	I:C1384514
deceives	O
diagnosis	B:C0430022
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O

The	O
identification	O
of	O
a	O
curable	O
form	O
of	O
primary	B:C1384514
aldosteronism	I:C1384514
can	O
be	O
beneficial	O
particularly	O
in	O
some	O
subgroups	B:C1515021
of	O
patients	O
,	O
namely	O
those	O
with	O
drug	B:C0013227
-	O
resistant	O
hypertension	B:C0020538
,	O
who	O
are	O
at	O
high	B:C0332167
risk	I:C0332167
of	I:C0332167
primary	B:C1384514
aldosteronism	I:C1384514
.	O

An	O
aggressive	O
diagnostic	B:C0430022
approach	I:C0430022
is	O
necessary	O
in	O
these	O
patients	O
,	O
who	O
can	O
benefit	O
most	O
from	O
an	O
accurate	O
diagnosis	B:C0430022
.	O

Knowledge	B:C0376554
of	O
the	O
sodium	O
intake	O
and	O
drug	O
effects	O
on	O
the	O
aldosterone	O
-	O
renin	O
ratio	O
is	O
a	O
key	O
element	O
for	O
the	O
diagnosis	B:C0430022
in	O
these	O
challenging	O
cases	O
.	O

With	O
the	O
latest	O
work	B:C0750430
-	I:C0750430
up	I:C0750430
endorsed	O
by	O
the	O
Endocrine	B:C0162791
Society	I:C0162791
Guidelines	I:C0162791
and	O
supported	O
by	O
the	O
results	O
of	O
the	O
AQUARR	B:C2603343
Study	I:C2603343
,	O
the	O
diagnostic	O
algorithm	O
for	O
Primary	B:C1384514
aldosteronism	I:C1384514
can	O
be	O
substantially	O
simplified	O
.	O

This	O
means	O
skipping	O
the	O
so	O
-	O
called	O
confirmatory	O
tests	O
in	O
most	O
cases	O
and	O
thus	O
rendering	O
the	O
screening	B:C1710031
of	O
Primary	B:C1384514
aldosteronism	I:C1384514
feasible	O
and	O
affordable	O
.	O

Hence	O
,	O
most	O
centers	B:C0475309
can	O
nowadays	O
exploit	O
use	O
of	O
a	O
cost	O
-	O
effective	O
strategy	O
to	O
screen	B:C0220908
for	O
patients	O
with	O
primary	B:C1384514
aldosteronism	I:C1384514
.	O

At	O
variance	O
,	O
the	O
identification	O
of	O
primary	B:C1384514
aldosteronism	I:C1384514
subtypes	B:C0449560
,	O
which	O
involves	O
adrenal	B:C0457942
vein	I:C0457942
sampling	I:C0457942
(	O
adrenal	B:C0457942
vein	I:C0457942
sampling	I:C0457942
)	O
,	O
should	O
only	O
be	O
undertaken	O
at	O
tertiary	B:C0587437
referral	I:C0587437
centers	I:C0587437
that	O
have	O
experience	B:C0237607
in	O
performing	O
and	O
interpreting	O
this	O
minimally	B:C0430022
invasive	I:C0430022
test	I:C0430022
.	O

Overall	O
,	O
long	O
-	O
term	O
cure	O
biochemical	O
cure	O
can	O
be	O
consistently	O
achieved	O
when	O
adrenalectomy	B:C0001632
is	O
based	O
on	O
adrenal	B:C0457942
vein	I:C0457942
sampling	I:C0457942
-	O
based	O
identification	O
of	O
lateralized	O
aldosterone	B:C0002006
excess	O
.	O

Moreover	O
,	O
long	O
-	O
term	O
cure	O
of	O
hypertension	B:C0020538
,	O
defined	O
as	O
no	O
need	O
for	O
antihypertensive	B:C0003364
drug	I:C0003364
treatment	B:C0013216
,	O
can	O
be	O
achieved	O
in	O
about	O
45	O
%	O
of	O
the	O
cases	O
,	O
with	O
an	O
additional	O
40	O
%	O
showing	O
a	O
marked	O
improvement	O
in	O
blood	B:C1753303
pressure	I:C1753303
control	I:C1753303
.	O

Lack	O
of	O
blood	B:C0005823
pressure	I:C0005823
normalization	O
can	O
be	O
explained	O
by	O
misdiagnosis	B:C0679838
and	O
/	O
or	O
concomitant	O
essential	B:C0085580
hypertension	I:C0085580
.	O

